Pain News and Research

Latest Pain News and Research

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

GlaxoSmithKline announced today that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, including BEXSERO (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18).

25 Jun 2015

FDA provides safety update about Essure Birth Control Implant

The FDA first announced their intention to provide a safety update about Essure late yesterday evening. Today's much anticipated report comes on the heals of a private citizen petition that raised serious concerns about the Essure Birth Control Implant and resulted in the launch of an FDA investigation into the birth control device.

25 Jun 2015

Study finds an organic cause for patients with functional dyspepsia

How many times patients with gastrointestinal disorders have been told "There is nothing wrong, nothing organic, it's all you head". But the pain is real.

24 Jun 2015

Overuse injuries more common in girls participating in high school sports

A new study performed by researchers at The Ohio State University Wexner Medical Center shows that when it comes to overuse injuries in high school sports, girls are at a much higher risk than boys.

24 Jun 2015

FDA accepts proposed brand name Invossa for TissueGene-C

TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.

24 Jun 2015

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.

24 Jun 2015

FASEB honors Max Planck Florida scientist with Glaxo Smith Kline Neuroscience Discovery Award

The Federation of American Societies for Experimental Biology has honored Samuel M. Young, Jr. Ph.D., a Max Planck Research Group Leader at Max Planck Florida Institute for Neuroscience, with the Glaxo Smith Kline Neuroscience Discovery Award.

23 Jun 2015

Roche unveils series of new diagnostic technologies at EuroMedLab

Today at the 21st annual meeting of the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines in Paris, France, Roche unveiled a series of new diagnostic technologies.

23 Jun 2015

New research could help reverse side effects of acetaminophen overdose

New research could help reverse deadly side effects caused by excessive doses of the drug acetaminophen, the major ingredient in Tylenol and many other over-the-counter and prescription medicines.

23 Jun 2015

Opioid offers pain relief for Parkinson’s patients

Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows.

22 Jun 2015

Wockhardt obtains final approval from FDA for marketing 5mg/ 5ml of Oxycodone HCl liquid

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 5mg/ 5ml of Oxycodone HCl liquid which is used in treatment of moderate to severe acute and chronic pain. Wockhardt is launching the product soon and will be amongst the few generic versions of this product in the market.

22 Jun 2015

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron.

22 Jun 2015

New research sheds light on molecular architecture of receptors linked to many brain diseases

Scientists at The Scripps Research Institute have teamed up with several other institutions and pharmaceutical companies, including the University of Southern California (USC), San Diego's Receptos Inc. and Japanese company Ono Pharmaceutical Co., Ltd., to publish the first 3D structures of a receptor implicated in many diseases of the brain and in normal physiology throughout the body.

22 Jun 2015

TSRI scientists devise powerful set of chemical methods to explore protein biology

Scientists at The Scripps Research Institute (TSRI) have devised a powerful set of chemical methods for exploring the biology of proteins.

22 Jun 2015

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API).

22 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis.

19 Jun 2015

Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine.

19 Jun 2015

Effective medical communication missing between physicians and patients with chronic migraine

Many patients with chronic migraine (CM) receive suboptimal medical treatment even when they seek medical care. Reporting at the annual scientific meeting of the American Headache Society, researchers found that the majority of clinical encounters between CM patients and physicians were missing essential components of effective communication.

19 Jun 2015

New study launched in Liberia to better understand health consequences of Ebola virus disease

The Liberia-U.S. clinical research partnership known as PREVAIL has launched a study of people in Liberia who have survived Ebola virus disease (EVD) within the past two years. The study investigators hope to better understand the long-term health consequences of EVD, determine if survivors develop immunity that will protect them from future Ebola infection, and assess whether previously EVD-infected individuals can transmit infection to close contacts and sexual partners.

18 Jun 2015

Pain News and Research

Latest Pain News and Research

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

FDA provides safety update about Essure Birth Control Implant

Study finds an organic cause for patients with functional dyspepsia

Overuse injuries more common in girls participating in high school sports

FDA accepts proposed brand name Invossa for TissueGene-C

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

FASEB honors Max Planck Florida scientist with Glaxo Smith Kline Neuroscience Discovery Award

Roche unveils series of new diagnostic technologies at EuroMedLab

New research could help reverse side effects of acetaminophen overdose

Opioid offers pain relief for Parkinson’s patients

Wockhardt obtains final approval from FDA for marketing 5mg/ 5ml of Oxycodone HCl liquid

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

New research sheds light on molecular architecture of receptors linked to many brain diseases

TSRI scientists devise powerful set of chemical methods to explore protein biology

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Effective medical communication missing between physicians and patients with chronic migraine

New study launched in Liberia to better understand health consequences of Ebola virus disease

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Pain News and Research

Latest Pain News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in